Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Jul-Sep;13(3):163-6.
doi: 10.4103/0972-5229.58544.

Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome

Deven Juneja  1 , S Mohan, Vivek V Veturi, Palepu B Gopal
Affiliations
Case Reports

Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome

Deven Juneja et al. Indian J Crit Care Med. 2009 Jul-Sep.

Abstract

Results of the PROWESS trial suggested that heparin may reduce the efficacy of recombinant human activated protein C (rhAPC) and the XPRESS study also showed increased bleeding complications in patients receiving heparin with rhAPC. Although it has been shown that heparin prophylaxis may be used along with rhAPC, no study has shown the interaction between continuous heparin infusion and rhAPC. Here, we report a case of severe sepsis with pulmonary embolism who was concurrently administered heparin and rhAPC infusions, with positive results and no bleeding complications.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Electrocardiograph showing S wave in lead I, Q wave in lead III and T wave inversion in lead III (S1Q3T3 pattern)
Figure 2
Figure 2
CT pulmonary angiography scan showing the filling defects (marked by arrows) in the right lower lobe segmental artery, which is suggestive of pulmonary embolism
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10. - PubMed
    1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. - PubMed
    1. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24:663–72. - PubMed
    1. Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med. 2008;36:2973–9. - PubMed
    1. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA. 2003;290:238–47. - PubMed

Publication types

LinkOut - more resources